Description: I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.
Home Page: www.i-mabbiopharma.com
IMAB Technical Analysis
New Bund Center
Shanghai,
200124
China
Phone:
86 21 6057 8000
Officers
| Name | Title |
|---|---|
| Dr. Jingwu Zhang Zang M.D., Ph.D. | Founder & Chairman |
| Dr. Andrew X. Zhu M.D., Ph.D. | Member of Scientific Advisory Board, Pres, Acting CEO & Director |
| Dr. Jerry Wang | Co-Founder & Chief Scientific Officer |
| Mr. Richard L. Yeh M.B.A. | Interim CFO, COO & Director |
| Mr. Tianyi Zhang | VP of Investor Relations |
| Mr. Cheng Li | Chief Legal Officer |
| Ms. Gigi Qi Feng | Chief Communications Officer |
| Dr. Weiming Tang Ph.D. | Exec. VP of Global Bus. Devel. & Chief Bus. Officer |
| Dr. Fernando J. Salle´s Ph.D. | Sr. VP and Head of U.S. & EU Bus. Devel. |
| Mr. Ivan Yifei Zhu | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5874 |
| Price-to-Sales TTM: | 2.5452 |
| IPO Date: | 2020-01-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 378 |